Senator Elizabeth Warren (D-Mass.) and a group of lawmakers are urging the Biden administration to provide updates on its review of the government’s right to seize patents on high-priced drugs that have been developed using public funds. In a letter addressed to the Department of Health and Human Services and Commerce, released by The Hill, the lawmakers are calling for greater transparency on a working group that is responsible for reviewing the administration’s “march-in rights”. Under a 1980 law, the government has the authority to take control of a private company’s patent and licence the product to other manufacturers if it is not made available to the public on reasonable terms. The group of lawmakers is requesting more information about the working group’s membership, process, timeline, and scope of work. Additionally, legislators are seeking a list of patents that have benefited from government resources while ensuring the process remains independent of corporate interests. The Biden administration has already announced a plan to review its march-in authority and develop criteria that includes pricing for using the rights. The Inflation Reduction Act permits Medicare to negotiate drug prices, but Warren and progressives are pushing for greater action to reduce drug prices, including breaking patents.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
